Literature DB >> 7830767

Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain.

K D Beck1, J Valverde, T Alexi, K Poulsen, B Moffat, R A Vandlen, A Rosenthal, F Hefti.   

Abstract

Glial-cell-line-derived neurotrophic factor (GDNF) promotes survival of embryonic dopaminergic neurons in culture, and its expression pattern suggests a role as a transient target-derived trophic factor for dopaminergic neurons of the substantia nigra. These neurons participate in the control of motor activity, emotional status and cognition, and they degenerate in Parkinson's disease for unknown reasons. To test whether GDNF has a trophic effect on dopaminergic neurons in the adult brain, we used a rat model in which these neurons are induced to degenerate by transecting their axons within the medial forebrain bundle. We report here that axotomy resulted in loss of half the tyrosine hydroxylase-expressing neurons in the substantia nigra. This loss was largely prevented by repeated injections of GDNF adjacent to the substantia nigra. Our findings suggest that GDNF or related molecules may be useful for the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7830767     DOI: 10.1038/373339a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  103 in total

1.  Expression of GDNF and GDNFR-alpha mRNAs in muscles of patients with motor neuron diseases.

Authors:  M Yamamoto; N Mitsuma; A Inukai; Y Ito; M Li; T Mitsuma; G Sobue
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

2.  Role for GDNF in biochemical and behavioral adaptations to drugs of abuse.

Authors:  C J Messer; A J Eisch; W A Carlezon; K Whisler; L Shen; D H Wolf; H Westphal; F Collins; D S Russell; E J Nestler
Journal:  Neuron       Date:  2000-04       Impact factor: 17.173

3.  Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.

Authors:  E F Espejo; M C Gonzalez-Albo; J P Moraes; F El Banoua; J A Flores; I Caraballo
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

4.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

5.  Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS.

Authors:  M Trupp; N Belluardo; H Funakoshi; C F Ibáñez
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

Review 6.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 7.  Neurotoxins as Preclinical Models for Parkinson's Disease.

Authors:  Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2018-01-08       Impact factor: 3.911

8.  Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.

Authors:  Sebastien Carnicella; Somayeh Ahmadiantehrani; Dao-Yao He; Carsten K Nielsen; Selena E Bartlett; Patricia H Janak; Dorit Ron
Journal:  Biol Psychiatry       Date:  2009-02-20       Impact factor: 13.382

Review 9.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons.

Authors:  K Krieglstein; P Henheik; L Farkas; J Jaszai; D Galter; K Krohn; K Unsicker
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.